Your browser doesn't support javascript.
loading
Epicutaneous immunotherapy protects cashew-sensitized mice from anaphylaxis.
Pelletier, Benjamin; Perrin, Audrey; Assoun, Noémie; Plaquet, Camille; Oreal, Nathalie; Gaulme, Laetitia; Bouzereau, Adeline; Labernardière, Jean-Louis; Ligouis, Mélanie; Dioszeghy, Vincent; Wavrin, Sophie; Matthews, Katie; Porcheray, Fabrice; Sampson, Hugh A; Hervé, Pierre-Louis.
Afiliación
  • Pelletier B; DBV Technologies, Montrouge, France.
  • Perrin A; DBV Technologies, Montrouge, France.
  • Assoun N; DBV Technologies, Montrouge, France.
  • Plaquet C; DBV Technologies, Montrouge, France.
  • Oreal N; DBV Technologies, Montrouge, France.
  • Gaulme L; DBV Technologies, Montrouge, France.
  • Bouzereau A; DBV Technologies, Montrouge, France.
  • Labernardière JL; DBV Technologies, Montrouge, France.
  • Ligouis M; DBV Technologies, Montrouge, France.
  • Dioszeghy V; DBV Technologies, Montrouge, France.
  • Wavrin S; DBV Technologies, Montrouge, France.
  • Matthews K; DBV Technologies, New York, NY, USA.
  • Porcheray F; DBV Technologies, Montrouge, France.
  • Sampson HA; DBV Technologies, New York, NY, USA.
  • Hervé PL; DBV Technologies, Montrouge, France.
Allergy ; 76(4): 1213-1222, 2021 04.
Article en En | MEDLINE | ID: mdl-32996148
ABSTRACT

BACKGROUND:

The prevalence of tree nut allergy has increased worldwide, and cashew has become one of the most common food allergens. More critically, cashew allergy is frequently associated with severe anaphylaxis. Despite the high medical need, no approved treatment is available and strict avoidance and preparedness for prompt treatment of allergic reactions are considered dual standard of care. In the meantime, Phase III study results suggest investigational epicutaneous immunotherapy (EPIT) may be a relevant and safe treatment for peanut allergy and may improve the quality of life for many peanut allergic children.

OBJECTIVE:

We aimed to evaluate the capacity of EPIT to provide protection against cashew-induced anaphylaxis in a relevant mouse model.

METHODS:

The efficacy of EPIT was evaluated by applying patches containing cashew allergens to cashew-sensitized mice. As negative control, sham mice received patches containing excipient. Following treatment, mice were challenged orally to cashew and anaphylactic symptoms, as well as plasmatic levels of mast-cell proteases (mMCP)-1/7, were quantified.

RESULTS:

Of 16 weeks of EPIT significantly protects against anaphylaxis by promoting a faster recovery of challenged mice. This protection was characterized by a significant reduction of temperature drop and clinical symptoms, 60 minutes after challenge. This was associated with a decrease in mast-cell reactivity as attested by the reduction of mMCP-1/7 in plasma, suggesting that EPIT specifically decrease IgE-mediated anaphylaxis.

CONCLUSION:

We demonstrate that EPIT markedly reduced IgE-mediated allergic reactions in a mouse model of cashew allergy, which suggests that EPIT may be a relevant approach to treating cashew allergy.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Anacardium / Anafilaxia Tipo de estudio: Risk_factors_studies Límite: Animals Idioma: En Revista: Allergy Año: 2021 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Anacardium / Anafilaxia Tipo de estudio: Risk_factors_studies Límite: Animals Idioma: En Revista: Allergy Año: 2021 Tipo del documento: Article País de afiliación: Francia